Therapeutic Solutions International Announces Antigen Specific Blockade of Pathological Immune Response in Multiple Sclerosis Model Using “Tattoo Gun” Immunization

Secondary Finding Demonstrates Tattooing Skin with Tolerogenic Genes AIRE or FoxP3 “Balances” Immune System to Stop Autoimmunity

ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced novel data and patent filing today on the unanticipated finding that multiple microinjections of myelin basic protein derived peptides together with various agents that block dendritic cell maturation leads to substantially higher suppression of multiple sclerosis symptomology in the experimental autoimmune encephalitis model of the disease as compared to various conventional means of administration.

Previously other groups have used tattoo gun-based mechanisms to stimulate immune responses based on the theoretical advantage that a high number of microinjections results in a greater number of antigen presenting cells received to target immunogens.

“Utilizing a “tattoo gun” approach evokes a substantial degree of inflammation, which is classically believed to stimulate immunity. Surprisingly we found that in the presence of inhibitors of dendritic cell maturation factors that this approach led to potent generation of “suppressive” immune cells,” said David Barnett, Consultant to the Company.

“The quest to replicate the biological condition of pregnancy in which immunologically distinct tissues are not rejected by the host has been the Holy Grail of immunologists for the past century,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “It would be extremely ironic if something as simple as a tattoo gun was the answer.”

The concept of modulating antigen presentation to inhibit pathological immunity has previously been described. However, the unexpected potency of the large surface area of injection only achievable by a tattoo gun was completely unexpected. Furthermore, the finding that dermal transfection of the AIRE gene, as well as the FoxP3 gene was able to dampen autoimmune pathology and was completely unexpected.

“While we are highly focused on execution of our Phase III COVID clinical trial, through our multiple collaborations we discover multiple unexpected findings on a regular basis,” said Timothy Dixon, President, and CEO of the Company. “The advantage of possessing a patent portfolio of 70 issued and pending patents is that our shareholders may benefit not only from successes of products we develop but also from licensing fees in a diverse area of biotechnology”.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.